Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.

Haaxma CA, Horstink MW, Zijlmans JC, Lemmens WA, Bloem BR, Borm GF.

J Parkinsons Dis. 2015;5(4):847-53. doi: 10.3233/JPD-150532.

PMID:
26444087
2.

Artistic occupations are associated with a reduced risk of Parkinson's disease.

Haaxma CA, Borm GF, van der Linden D, Kappelle AC, Bloem BR.

J Neurol. 2015 Sep;262(9):2171-6. doi: 10.1007/s00415-015-7828-y. Epub 2015 Jul 3.

3.

Small studies are more heterogeneous than large ones: a meta-meta-analysis.

IntHout J, Ioannidis JP, Borm GF, Goeman JJ.

J Clin Epidemiol. 2015 Aug;68(8):860-9. doi: 10.1016/j.jclinepi.2015.03.017. Epub 2015 Apr 2.

4.

Ancillary investigations to diagnose parkinsonism: a prospective clinical study.

Aerts MB, Esselink RA, Abdo WF, Meijer FJ, Drost G, Norgren N, Janssen MJ, Borm GF, Bloem BR, Verbeek MM.

J Neurol. 2015 Feb;262(2):346-56. doi: 10.1007/s00415-014-7568-4. Epub 2014 Nov 9.

PMID:
25381460
5.
6.

Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.

Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28.

PMID:
24166522
7.

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC.

Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.

PMID:
24104881
8.

Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT).

van der Marck MA, Munneke M, Mulleners W, Hoogerwaard EM, Borm GF, Overeem S, Bloem BR; IMPACT study group.

Lancet Neurol. 2013 Oct;12(10):947-56. doi: 10.1016/S1474-4422(13)70196-0. Epub 2013 Aug 27.

PMID:
23988337
9.

Impact of falls and fear of falling on health-related quality of life in patients with Parkinson's disease.

Grimbergen YA, Schrag A, Mazibrada G, Borm GF, Bloem BR.

J Parkinsons Dis. 2013 Jan 1;3(3):409-13. doi: 10.3233/JPD-120113.

PMID:
23948987
10.

Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.

Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists' Group of the Netherlands (BOOG).

Eur J Cancer. 2013 Oct;49(15):3102-10. doi: 10.1016/j.ejca.2013.06.012. Epub 2013 Jul 10.

PMID:
23850450
11.

Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.

Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29.

PMID:
23630211
12.

Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemia-reperfusion injury in humans.

van den Munckhof I, Riksen N, Seeger JP, Schreuder TH, Borm GF, Eijsvogels TM, Hopman MT, Rongen GA, Thijssen DH.

Am J Physiol Heart Circ Physiol. 2013 Jun 15;304(12):H1727-32. doi: 10.1152/ajpheart.00054.2013. Epub 2013 Apr 19.

13.

Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial.

van Nimwegen M, Speelman AD, Overeem S, van de Warrenburg BP, Smulders K, Dontje ML, Borm GF, Backx FJ, Bloem BR, Munneke M; ParkFit Study Group.

BMJ. 2013 Mar 1;346:f576. doi: 10.1136/bmj.f576.

14.

Effectiveness of occupational therapy in Parkinson's disease: study protocol for a randomized controlled trial.

Sturkenboom IH, Graff MJ, Borm GF, Adang EM, Nijhuis-van der Sanden MW, Bloem BR, Munneke M.

Trials. 2013 Feb 2;14:34. doi: 10.1186/1745-6215-14-34.

15.

Effectiveness of multidisciplinary care for Parkinson's disease: a randomized, controlled trial.

van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M.

Mov Disord. 2013 May;28(5):605-11. doi: 10.1002/mds.25194. Epub 2012 Nov 19.

PMID:
23165981
16.

Outcome prediction in moderate and severe traumatic brain injury: a focus on computed tomography variables.

Jacobs B, Beems T, van der Vliet TM, van Vugt AB, Hoedemaekers C, Horn J, Franschman G, Haitsma I, van der Naalt J, Andriessen TM, Borm GF, Vos PE.

Neurocrit Care. 2013 Aug;19(1):79-89. doi: 10.1007/s12028-012-9795-9.

PMID:
23138545
17.

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease.

Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, Dalaker TO, Beyer MK, Aarsland D, Andreasson U, Lange J, Tysnes OB, Zivadinov R, Larsen JP.

J Neurol Neurosurg Psychiatry. 2013 May;84(5):537-43. doi: 10.1136/jnnp-2012-303808. Epub 2012 Oct 31.

PMID:
23117496
18.

Obtaining evidence by a single well-powered trial or several modestly powered trials.

IntHout J, Ioannidis JP, Borm GF.

Stat Methods Med Res. 2016 Apr;25(2):538-52. doi: 10.1177/0962280212461098. Epub 2012 Oct 14.

PMID:
23070590
19.

Meier-Gorlin syndrome: growth and secondary sexual development of a microcephalic primordial dwarfism disorder.

de Munnik SA, Otten BJ, Schoots J, Bicknell LS, Aftimos S, Al-Aama JY, van Bever Y, Bober MB, Borm GF, Clayton-Smith J, Deal CL, Edrees AY, Feingold M, Fryer A, van Hagen JM, Hennekam RC, Jansweijer MC, Johnson D, Kant SG, Opitz JM, Ramadevi AR, Reardon W, Ross A, Sarda P, Schrander-Stumpel CT, Sluiter AE, Temple IK, Terhal PA, Toutain A, Wise CA, Wright M, Skidmore DL, Samuels ME, Hoefsloot LH, Knoers NV, Brunner HG, Jackson AP, Bongers EM.

Am J Med Genet A. 2012 Nov;158A(11):2733-42. doi: 10.1002/ajmg.a.35681. Epub 2012 Sep 28.

PMID:
23023959
20.

Development and external validation of a new PTA assessment scale.

Jacobs B, van Ekert J, Vernooy LP, Dieperink P, Andriessen TM, Hendriks MP, van Vugt AB, Emons MA, Borm GF, Vos PE.

BMC Neurol. 2012 Aug 8;12:69.

21.

Health status one year after TransInguinal PrePeritoneal inguinal hernia repair and Lichtenstein's method: an analysis alongside a randomized clinical study.

Koning GG, de Vries J, Borm GF, Koeslag L, Vriens PW, van Laarhoven CJ.

Hernia. 2013 Jun;17(3):299-306. doi: 10.1007/s10029-012-0963-9. Epub 2012 Aug 8.

PMID:
22872429
22.

The impact of occupational therapy in Parkinson's disease: a randomized controlled feasibility study.

Sturkenboom IH, Graff MJ, Borm GF, Veenhuizen Y, Bloem BR, Munneke M, Nijhuis-van der Sanden MW.

Clin Rehabil. 2013 Feb;27(2):99-112. doi: 10.1177/0269215512448382. Epub 2012 Jul 18.

PMID:
22811447
23.

First trial reactions and habituation rates over successive balance perturbations in Parkinson's disease.

Nanhoe-Mahabier W, Allum JH, Overeem S, Borm GF, Oude Nijhuis LB, Bloem BR.

Neuroscience. 2012 Aug 16;217:123-9. doi: 10.1016/j.neuroscience.2012.03.064. Epub 2012 Apr 24.

PMID:
22542872
24.

Absence of clinically relevant growth acceleration in untreated children with non-classical congenital adrenal hyperplasia.

Pijnenburg-Kleizen KJ, Borm GF, Otten BJ, Schott DA, van den Akker EL, Stokvis-Brantsma WH, Voorhoeve PG, Bakker B, Claahsen-van der Grinten HL.

Horm Res Paediatr. 2012;77(3):164-9. doi: 10.1159/000337217. Epub 2012 Apr 12.

PMID:
22508177
25.

A simple sample size formula for analysis of covariance in cluster randomized trials.

Teerenstra S, Eldridge S, Graff M, de Hoop E, Borm GF.

Stat Med. 2012 Sep 10;31(20):2169-78. doi: 10.1002/sim.5352. Epub 2012 Apr 11.

PMID:
22495809
26.

Relevant impact of central pathology review on nodal classification in individual breast cancer patients.

Vestjens JH, Pepels MJ, de Boer M, Borm GF, van Deurzen CH, van Diest PJ, van Dijck JA, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC.

Ann Oncol. 2012 Oct;23(10):2561-6. Epub 2012 Apr 11.

PMID:
22495317
27.

Cost-effectiveness of adjuvant systemic therapy in low-risk breast cancer patients with nodal isolated tumor cells or micrometastases.

de Boer M, Adang EM, Van Dycke KC, van Dijck JA, Borm GF, Seferina SC, van Deurzen CH, van Diest PJ, Bult P, Donders AR, Tjan-Heijnen VC.

Ann Oncol. 2012 Oct;23(10):2585-91. Epub 2012 Mar 26.

PMID:
22449731
28.

Cardiovascular responses during a submaximal exercise test in patients with Parkinson's disease.

Speelman AD, Groothuis JT, van Nimwegen M, van der Scheer ES, Borm GF, Bloem BR, Hopman MT, Munneke M.

J Parkinsons Dis. 2012;2(3):241-7. doi: 10.3233/JPD-2012-012111.

PMID:
23938232
29.

Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.

Pepels MJ, de Boer M, Bult P, van Dijck JA, van Deurzen CH, Menke-Pluymers MB, van Diest PJ, Borm GF, Tjan-Heijnen VC.

Ann Surg. 2012 Jan;255(1):116-21. doi: 10.1097/SLA.0b013e31823dc616.

PMID:
22183034
30.

Body mass index in Parkinson's disease: a meta-analysis.

van der Marck MA, Dicke HC, Uc EY, Kentin ZH, Borm GF, Bloem BR, Overeem S, Munneke M.

Parkinsonism Relat Disord. 2012 Mar;18(3):263-7. doi: 10.1016/j.parkreldis.2011.10.016. Epub 2011 Nov 18.

PMID:
22100523
31.

Contribution of routine brain MRI to the differential diagnosis of parkinsonism: a 3-year prospective follow-up study.

Meijer FJ, Aerts MB, Abdo WF, Prokop M, Borm GF, Esselink RA, Goraj B, Bloem BR.

J Neurol. 2012 May;259(5):929-35. doi: 10.1007/s00415-011-6280-x. Epub 2011 Oct 19.

32.

Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location.

Vestjens JH, de Boer M, van Diest PJ, van Deurzen CH, van Dijck JA, Borm GF, Adang EM, Bult P, Tjan-Heijnen VC.

Breast Cancer Res Treat. 2012 Jan;131(2):645-51. doi: 10.1007/s10549-011-1771-0. Epub 2011 Sep 17.

PMID:
21927853
33.

Studies with group treatments required special power calculations, allocation methods, and statistical analyses.

Faes MC, Reelick MF, Perry M, Olde Rikkert MG, Borm GF.

J Clin Epidemiol. 2012 Feb;65(2):138-46. doi: 10.1016/j.jclinepi.2011.05.007. Epub 2011 Sep 9.

34.

The "best balance" allocation led to optimal balance in cluster-controlled trials.

de Hoop E, Teerenstra S, van Gaal BG, Moerbeek M, Borm GF.

J Clin Epidemiol. 2012 Feb;65(2):132-7. doi: 10.1016/j.jclinepi.2011.05.006. Epub 2011 Aug 12.

35.

Reproducibility and validity of patient-rated assessment of speech, swallowing, and saliva control in Parkinson's disease.

Kalf JG, Borm GF, de Swart BJ, Bloem BR, Zwarts MJ, Munneke M.

Arch Phys Med Rehabil. 2011 Jul;92(7):1152-8. doi: 10.1016/j.apmr.2011.02.011.

PMID:
21704797
36.

Physical inactivity in Parkinson's disease.

van Nimwegen M, Speelman AD, Hofman-van Rossum EJ, Overeem S, Deeg DJ, Borm GF, van der Horst MH, Bloem BR, Munneke M.

J Neurol. 2011 Dec;258(12):2214-21. doi: 10.1007/s00415-011-6097-7. Epub 2011 May 26.

37.

Pathophysiology of diurnal drooling in Parkinson's disease.

Kalf JG, Munneke M, van den Engel-Hoek L, de Swart BJ, Borm GF, Bloem BR, Zwarts MJ.

Mov Disord. 2011 Aug 1;26(9):1670-6. doi: 10.1002/mds.23720. Epub 2011 Apr 11.

PMID:
21484876
38.

Multifactorial fall prevention for pairs of frail community-dwelling older fallers and their informal caregivers: a dead end for complex interventions in the frailest fallers.

Faes MC, Reelick MF, Melis RJ, Borm GF, Esselink RA, Rikkert MG.

J Am Med Dir Assoc. 2011 Jul;12(6):451-8. doi: 10.1016/j.jamda.2010.11.006. Epub 2010 Dec 24.

PMID:
21450224
39.

The SAFE or SORRY? programme. part II: effect on preventive care.

van Gaal BG, Schoonhoven L, Mintjes JA, Borm GF, Koopmans RT, van Achterberg T.

Int J Nurs Stud. 2011 Sep;48(9):1049-57. doi: 10.1016/j.ijnurstu.2011.02.018. Epub 2011 Mar 26.

PMID:
21440891
40.

Fewer adverse events as a result of the SAFE or SORRY? programme in hospitals and nursing homes. part i: primary outcome of a cluster randomised trial.

van Gaal BG, Schoonhoven L, Mintjes JA, Borm GF, Hulscher ME, Defloor T, Habets H, Voss A, Vloet LC, Koopmans RT, van Achterberg T.

Int J Nurs Stud. 2011 Sep;48(9):1040-8. doi: 10.1016/j.ijnurstu.2011.02.017. Epub 2011 Mar 17.

PMID:
21419411
41.

Monitoring of walking in Parkinson's disease: validation of an ambulatory activity monitor.

Speelman AD, van Nimwegen M, Borm GF, Bloem BR, Munneke M.

Parkinsonism Relat Disord. 2011 Jun;17(5):402-4. doi: 10.1016/j.parkreldis.2011.02.006. Epub 2011 Mar 1. No abstract available.

PMID:
21367643
42.

Computed tomography and outcome in moderate and severe traumatic brain injury: hematoma volume and midline shift revisited.

Jacobs B, Beems T, van der Vliet TM, Diaz-Arrastia RR, Borm GF, Vos PE.

J Neurotrauma. 2011 Feb;28(2):203-15. doi: 10.1089/neu.2010.1558. Epub 2011 Feb 5.

PMID:
21294647
43.

GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study.

Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, Edwards M, Rosmalen CF, Vissers JL.

Neurology. 2010 Nov 16;75(20):1786-93. doi: 10.1212/WNL.0b013e3181fd62d2.

PMID:
21079180
44.

Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review.

Pepels MJ, Vestjens JH, de Boer M, Smidt M, van Diest PJ, Borm GF, Tjan-Heijnen VC.

Breast Cancer Res Treat. 2011 Jan;125(2):301-13. doi: 10.1007/s10549-010-1210-7. Epub 2010 Oct 24. Review.

PMID:
20972825
45.

Side of symptom onset affects motor dysfunction in Parkinson's disease.

Haaxma CA, Helmich RC, Borm GF, Kappelle AC, Horstink MW, Bloem BR.

Neuroscience. 2010 Nov 10;170(4):1282-5. doi: 10.1016/j.neuroscience.2010.07.030. Epub 2010 Aug 17.

PMID:
20723583
46.

Design and baseline characteristics of the ParkFit study, a randomized controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase physical activity in Parkinson patients.

van Nimwegen M, Speelman AD, Smulders K, Overeem S, Borm GF, Backx FJ, Bloem BR, Munneke M; ParkFit Study Group.

BMC Neurol. 2010 Aug 19;10:70. doi: 10.1186/1471-2377-10-70.

47.

The development of a screening instrument to select patients at risk of residual complaints after lumbar disc surgery.

den Boer JJ, Oostendorp RA, Evers AW, Beems T, Borm GF, Munneke M.

Eur J Phys Rehabil Med. 2010 Dec;46(4):497-503. Epub 2010 Jul 16.

48.

Timed motor tests can detect subtle motor dysfunction in early Parkinson's disease.

Haaxma CA, Bloem BR, Overeem S, Borm GF, Horstink MW.

Mov Disord. 2010 Jul 15;25(9):1150-6. doi: 10.1002/mds.23100.

PMID:
20629141
49.

A simple method for calculating power based on a prior trial.

Borm GF, Bloem BR, Munneke M, Teerenstra S.

J Clin Epidemiol. 2010 Sep;63(9):992-7. doi: 10.1016/j.jclinepi.2009.10.011. Epub 2010 Jun 22.

PMID:
20573484
50.

The role of nurses in the recognition and treatment of patients with sepsis in the emergency department: a prospective before-and-after intervention study.

Tromp M, Hulscher M, Bleeker-Rovers CP, Peters L, van den Berg DT, Borm GF, Kullberg BJ, van Achterberg T, Pickkers P.

Int J Nurs Stud. 2010 Dec;47(12):1464-73. doi: 10.1016/j.ijnurstu.2010.04.007. Epub 2010 May 21.

PMID:
20494356

Supplemental Content

Support Center